pancreatic cysts
Interpace Diagnostics to Cease PancraGen Testing After Losing CMS Reimbursement
The fate of its pancreatic cancer test had been in limbo for years, but with a newly active LCD from Medicare contractor Novitas, the firm has had to close the book on the assay.
The firm uses proprietary dyes and Raman spectroscopy to detect pancreatic cysts from small sample volumes.
Interpace, Rutgers, Mass General Sign Deal for Pancreatic Cyst Risk Assessment Biomarker
Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management.
Johns Hopkins Team Develops Test to Guide Pancreatic Cyst Treatment
The researchers have developed CompCyst, which uses clinical features, imaging, and molecular data, to guide pancreatic cysts treatment approaches.
Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.